An inclisiran-based treatment strategy reduces the need for therapy escalation to achieve low-density lipoprotein cholesterol goals: Exploratory findings from the VICTORION-Difference trial

Leqvio (inclisiran) - Novartis

Nexletol (bempedoic acid) - Esperion Therap, CSL Behring

ezetimibe - Generic mfg.

M Banach1; U Laufs2; U Schatz3; EB Winzer4; B Nowak5; U Kassner6; I Gouni Berthold7; C Metais8; L Lubyayi9; KD Molle10; A Achouba10; U Landmesser11

May 11, 2026